Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

BeaconMedIC

1 year
424 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.
Up Next Autoplay
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Category: General
1,200 Views
BeaconMedIC 10 months
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Category: Small Cell Lung Cancer
925 Views
BeaconMedIC 11 months
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Category: Non-Small Cell Lung Cancer
689 Views
BeaconMedIC 11 months
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Category: Non-Small Cell Lung Cancer
614 Views
BeaconMedIC 11 months
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
Category: Non-Small Cell Lung Cancer
549 Views
BeaconMedIC 11 months
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
Category: Non-Small Cell Lung Cancer
463 Views
BeaconMedIC 11 months
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Category: Non-Small Cell Lung Cancer
222 Views
BeaconMedIC 1 year
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Category: Immunotherapy
258 Views
BeaconMedIC 1 year
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Category: Small Cell Lung Cancer
333 Views
BeaconMedIC 1 year